One platform comparison of solubilization potential of dendrimer with some solubilizing agents

Drug Development and Industrial Pharmacy

Volumn 41, Issue 5, 2015, Pages 722-727

  Jain, Swati ^a   Kesharwani, Prashant ^a   Tekade, Rakesh K ^b   Jain, Narendra K ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b UNIVERSITY OF HAWAII AT HILO   (United States)

Author keywords

PEG 6000; Poly(propylene imine) dendrimers; Solubilization; Tween 80; Cyclodextrin

Indexed keywords

DENDRIMER; MACROGOL 6000; PACLITAXEL; POLY(PROPYLENE IMINE); POLYSORBATE 80; SOLUBILIZER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EXCIPIENT;

ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SOLUBILITY; DRUG SYNTHESIS; HEMOLYSIS; HUMAN; HYDROPHOBICITY; INFRARED SPECTROSCOPY; PH; SOLUBILIZATION; TOXICITY TESTING; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; MEDICINAL CHEMISTRY; PROCEDURES; SOLUBILITY; TIME FACTOR;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; DENDRIMERS; EXCIPIENTS; HEMOLYSIS; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; PACLITAXEL; SOLUBILITY; TIME FACTORS; TOXICITY TESTS;

EID: 84930358373     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2014.900077     Document Type: Article

References (47)

1. Jain NK, Tekade RK. Drug delivery strategies for poorly water-soluble drugs. Kent, UK: Wiley Blackwell Publisher; 2012:373-99.
2. Mohanachandran PS, Sindhumol PG, Kiran TS. Enhancement of solubility and dissolution rate: an overview. Pharmacie Globale Int J Comprehensive Pharm 2010;4:1-10.
3. Gajbhiye V, Palanirajan VK, Tekade RK, Jain NK. Dendrimers as therapeutic agents: a systematic review. J Pharm Pharmacol 2009; 61:989-1003.
4. Shukla M, Rathore P, Jain A, Nayak S. Enhanced solubility study of glipizide using different solubilization techniques. Int J Pharmacy Pharm Sci 2010;2:46-8.
5. Szejtli J. Cyclodextrins and their inclusion complexes. Budapest: Akademiai Kiado; 1982.
6. Loftsson T, Fridriksdottir H, Olafsdottir B, Gudmundson O. Solubilization and stabilization of drugs through cyclodextrin complexation. Acta Pharm Nord 1991;3:215-17.
7. Choi HG, Kim DD, Jun HW, et al. Improvement of dissolution and bioavalability of nitrendipine by inclusion in hydroxypropyl-b-cyclodextrin. Drug Dev Ind Pharm 2003;29:1085-94.
8. Youngren SR, Tekade RK, Gustilo B, et al. STAT6 siRNA matrix-loaded gelatin nanocarriers: formulation, characterization, and ex vivo proof of concept using adenocarcinoma cells. BioMed Res Int 2013;2013:858946.
9. Sugimoto M, Okagaki T, Narisawa S, et al. Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using water-soluble polymer. Int J Pharm 1998;160:11-19.
10. Gajbhiye V, Kumar PV, Tekade RK, Jain NK. Pharmaceutical and biomedical potential of pegylated dendrimers. Curr Pharm Des 2007;13:415-29.
11. Tekade RK, Chougule MB. Formulation development and evaluation of hybrid nanocarrier for cancer therapy: taguchi orthogonal array based design. BioMed Research Int 2013;2013:712678.
12. Ikeda K, Tomida H, Yotsuyanagi T. Micellar interaction of tetracycline antibiotics. Chem Pharm Bull 1977;25:1067-71.
13. Martin A, Bustamante P. Physical pharmacy. 4th ed. Philadelphia: Lea and Febiger; 1993:410-11.
14. Dwivedi P, Tekade RK, Jain NK. Nanoparticulate carrier mediated intranasal delivery of insulin for the restoration of memory signaling in alzheimer's disease. Curr Nanosci 2013;9:46-55.
15. Maheshwari RGS, Tekade RK, Sharma PA, et al. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment. Saudi Pharm J 2012;20:161-70.
16. Kurmi BD, Kayat J, Gajbhiye V, et al. Micro-and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv 2010;7:781-94.
17. Kayat J, Gajbhiye V, Tekade RK, Jain NK. Pulmonary toxicity of carbon nanotubes: a systematic report. Nanomedicine 2011;7:40-9.
18. Chauhan AS, Sridevi S, Chalasani KB, et al. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J Control Release 2003;90:335-43.
19. Thakur S, Tekade RK, Kesharwani P, Jain NK. The effect of polyethylene glycol spacer chain length on the tumor targeting potential of folate modified PPI dendrimers. J Nanoparticle Res 2013;15:1625-40.
20. Kesharwani P, Gajbhiye V, Tekade RK, Jain NK. Evaluation of dendrimer safety and efficacy through cell line studies. Curr Drug Targets 2011;12:1478-97.
21. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci 2014;39:268-307.
22. Gu L, Wu Zh, Qi X, et al. Polyamidomine dendrimers: an excellent drug carrier for improving the solubility and bioavailability of puerarin. Pharm Dev Technol 2013;18:1051-7.
23. Kalhapure RS, Kathiravan MK, Akamanchi KG, Govender T. Dendrimers-from organic synthesis to pharmaceutical applications: an update. Pharm Dev Technol 2013;10:1687-98.
24. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-14.
25. Panchagnula R. Pharmaceutical aspects of Paclitaxel. Int J Pharm 1998;172:1-15.
26. Dhakad RS, Tekade RK, Jain NK. Cancer targeting potential of folate targeted nanocarrier under comparative influence of tretinoin and dexamethasone. Curr Drug Deliv 2013;10:477-91.
27. Tekade RK, Dutta T, Gajbhiye V, Jain NK. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. J Microencapsul 2008;15:1-10.
28. Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Instr 1965;4:117-22.
29. Kesharwani P, Tekade RK, Jain NK. Spectrophotometric estimation of paclitaxel. Int J Adv Pharm Sci 2011;2:29-32.
30. Tekade RK, Emanuele AD, Elhissi A, et al. Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples. J Biomed Res 2013;27:394-405.
31. Singhai AK, Jain S, Jain NK. Evaluation of an aqueous injection of ketoprofen. Pharmazie 1997;52:149-51.
32. 2 receptor antagonist. Eur J Med Chem 2008;44:55-66.
33. Kesharwani P, Tekade RK, Gajbhiye V, et al. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendri-mers: a comparison. Nanomedicine 2011;7:295-304.
34. Mahapatra AK, Murthy PN, Biswal S, et al. Solid dispersions with polyethylene glycol 4000 and 20000. Int J Pharm Sci Tech 2010;4: 21-31.
35. Prajapati RN, Tekade RK, Gupta U, et al. Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. Mol Pharm 2009;6:940-50.
36. Szejtli J. Medicinal applications of cyclodextrins. Med Res Rev 1994;14:353-86.
37. Ahmed MO. Comparison of impact of the different hydrophilic carriers on the properties of piperazine-containing drug. Eur J Pharm Biopharm 2001;51:221-6.
38. Duijvenbode RCV, Borkovec M, Koper GJM. Acid base properties of poly (propylene imine) dendrimers. Polymer 1998; 39:2657-64.
39. Newkome GR, Moorefield CN, Baker GR, et al. Unimolecular micelles. Angew Chem Int Ed 1991;30:1178-80.
40. Tekade RK, Kumar PV, Jain NK. Dendrimers in oncology: an expanding horizon. Chem Rev 2009;109:49-87.
41. Hawker CJ, Wooley KL, Frechet JMJ. Unimolecular micelles and globular amphiphiles: dendritic macromolecules as novel recyclable solubilization agents. J Chem Soc Perkin Trans 1993;1:1287-97.
42. Stevelmens S, Hest JCM, Jansen JFGA, et al. Synthesis, characterisation and guest-host properties of inverted unimolecular micelles. J Am Chem Soc 1996;118:7398-9.
43. Gupta U, Agashe HB, Jain NK. Polypropylene imine dendrimer mediated solubility enhancement: effect of pH and functional groups of hydrophobes. J Pharm Pharmacol Sci 2007;10:358-67.
44. Tekade RK, Dutta T, Tyagi A, et al. Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. J Drug Target 2008;16: 758-72.
45. Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: let's meet the challenge. Int J Pharm 2010;15:122-42.
46. Mishra V, Gupta U, Jain NK. Influence of different generations of poly(propylene imine) dendrimers on human erythrocytes. Pharmazie 2010;65:891-5.
47. Kesharwani P, Gajbhiye V, Tekade RK, Jain NK. Evaluation of dendrimer safety and efficacy through cell line studies. Curr Drug Targets 2011;12:1478-97.